Abstract
* Injectable brodalumab (Siliq), a human monoclonal antibody that inhibits the release of inflammatory cytokines and chemokines, has been approved to treat moderate-to-severe plaque psoriasis.
* Because brodalumab may increase the risk of suicidal ideation and behavior, it is only available for those in the Food and Drug Administration's Risk Evaluation and Mitigation Strategy program.